Generally,
clinical outcome relies on blood glucose measurement;
however, advanced glycation endproducts (AGEs) are now
considered the more meaningful parameter in diabetic evaluation.
AGEs are heterogeneous substances generated from
sugars and proteins via Hodge pathway or Wolf and Namiki
pathways. Amadori’s product, such as A1C and fructosamine,
are produced in the early phase of Hodge pathway.